Drugs / Random Donor Plasma
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04346446 Comparator | Apr → May 2020 | COVID-19 | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Random Donor Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04346446 ↗ |
| Route | Other | “Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement” NCT04346446 ↗ |